Biopharmaceutical company Forte Biosciences Inc (NASDAQ: FBRX) on Monday reported additional data from its Phase 1b trial of FB102 in celiac disease, presented at the Tampere Celiac Disease Symposium in Finland on 12 September 2025.
FB102 reduced TCR γδ density by 1.5 from baseline compared to an increase of 3.9 on placebo (p=0.0007). Ki67-positive intraepithelial cell density, a marker of T cell proliferation, rose by 8.6 on placebo versus 2.5 on FB102 (p=0.0006). Natural killer cells declined by 95% with FB102, demonstrating inhibition of the IL-15 pathway, while no significant differences were observed in regulatory T cells between treatment and placebo.
Forte said the results reinforce the differentiated profile of FB102, its anti-CD122 monoclonal antibody in development for celiac disease and other autoimmune indications.
Phrontline Biopharma doses first patient in TJ101 Phase 1 clinical trial
Gene Solutions' mitochondrial therapy platform targeting neurological diseases secures patent
Zhimeng Biopharma's investigational drug gains Phase 2 epilepsy clinical trial approval in China
Avidity Biosciences prices upsized common stock public offering
Sanofi's SAR402663 granted FDA fast track designation for wet AMD
Endo to share PFI and PFA data at American Orthopaedic Foot & Ankle Society Annual Meeting
Diamyd Medical secures Eurasian patent for insulin-based antigen therapy in type 1 diabetes
Sobi's Biologics License Application for NASP in uncontrolled gout accepted by FDA
Hydrosome Labs announces promising fermentation breakthrough with ultrafine bubbles
Ionis receives FDA Breakthrough Therapy designation for ION582 in Angelman syndrome
AMO Pharma signs licence agreement with PHRI and Venca Research Inc to advance new study in ARVC
Saol Therapeutics receives US FDA Complete Response Letter for SL1009 (DCA) in PDCD